Factor B Inhibition for PNH With Extravascular Hemolysis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for paroxysmal nocturnal hemoglobinuria (PNH) using anti-C5 antibody therapies like eculizumab are ineffective in addressing extravascular hemolysis, leading to a high-unmet medical need, and there is a need for a more comprehensive approach to inhibit both intra- and extravascular hemolysis.
Innovation Solution
The use of LNP023, a Factor B inhibitor, administered orally at a dose of 200 mg twice daily, to inhibit the complement alternative pathway and prevent both intra- and extravascular hemolysis in PNH patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-C5 antibody therapy (eculizumab) is used to treat PNH, then intravascular hemolysis is controlled, but extravascular hemolysis persists due to C3 fragment deposition on red blood cells
Solution Approach 1:
The treatment approach is segmented into two distinct mechanisms: anti-C5 antibodies block terminal complement activation (intravascular hemolysis), while C3 inhibitors prevent C3 fragment deposition (extravascular hemolysis). This segmentation allows each therapy to target specific hemolysis pathways independently, resolving the contradiction between controlling intravascular while preventing extravascular hemolysis.
Solution Approach 2:
C3 inhibitors act as an intermediary that blocks the formation and deposition of C3 fragments on red blood cells, preventing opsonization and subsequent extravascular hemolysis by macrophages. This intermediary mechanism fills the therapeutic gap left by anti-C5 antibodies, which do not prevent C3 deposition.
2Reliability
If Factor B inhibition is implemented to block C3 convertase formation, then both intra- and extravascular hemolysis are prevented, but the complexity of the treatment mechanism increases
Solution Approach 1:
Factor B inhibition provides a universal mechanism that simultaneously addresses both intravascular and extravascular hemolysis through a single therapeutic action. By blocking C3 convertase formation, the treatment universally prevents complement-mediated hemolysis across both pathways, simplifying the overall treatment strategy despite the biological complexity of the complement system.
Solution Approach 2:
The treatment changes the key parameter of C3 convertase activity by inhibiting Factor B, thereby altering the complement cascade dynamics. This parameter change effectively reduces both intravascular and extravascular hemolysis by preventing C3 activation and fragment deposition, providing comprehensive protection through a single mechanistic intervention.
3Object-affected harmful factors
If C3 inhibitors are used to prevent C3 fragment deposition, then extravascular hemolysis is reduced, but intravascular hemolysis control may be compromised
Solution Approach 1:
The treatment merges two complementary mechanisms: C3 inhibition prevents extravascular hemolysis by blocking C3 fragment deposition, while anti-C5 antibodies maintain intravascular hemolysis control by blocking terminal complement activation. This combination therapy merges the benefits of both approaches, achieving comprehensive hemolysis control without compromising either pathway.
Solution Approach 2:
The combination therapy ensures continuity of useful action across both complement pathways: C3 inhibitors continuously prevent opsonization and extravascular hemolysis, while anti-C5 antibodies continuously block terminal complement activation and intravascular hemolysis. This continuous dual-action approach maintains reliable protection against both forms of hemolysis simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
LNP023 effectively reduces C3 deposition, normalizes hemolysis, increases red blood cell survival, and stabilizes hemoglobin levels, providing therapeutic benefits beyond current standards of care by inhibiting the complement pathway at multiple stages.
Implementation Method 1
LNP023 is a Factor B inhibitor that inhibits the complement alternative pathway
Implementation Method 2
LNP023 inhibits factor B (FB), a key protease of the complement alternative pathway (AP)
Implementation Method 3
PNH type red blood cells (RBCs) are attacked by complement leading to complement mediated lysis
Implementation Method 4
deposition of C3 fragments on the cell surface of PNH type erythrocytes lacking CD55 is not impacted, rendering the cells susceptible to extravascular hemolysis
Data Source
AI summary
Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.